Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Ir Med J ; 104(4): 122-3, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21675098

RESUMO

Patients receiving antitumour necrosis factor-alpha treatment may develop cutaneous reactions. This human monoclonal antibody is used in the treatment of chronic inflammatory diseases, including arthritis and inflammatory bowel disease. A variety of side effects have been documented ranging from infection and vasculitis through to systemic lupus erythematosus and psoriasis. We report on two arthritic patients treated with adalimumab (Humira, Abbot Laboratories, IL, USA) who developed new onset rashes that resolved with discontinuation of therapy. The frequency of these cutaneous reactions has not been fully established and may benefit from a centralised registry.


Assuntos
Anti-Inflamatórios/efeitos adversos , Antirreumáticos/efeitos adversos , Toxidermias/etiologia , Adalimumab , Adulto , Anticorpos Monoclonais , Anticorpos Monoclonais Humanizados , Artrite/tratamento farmacológico , Toxidermias/patologia , Humanos , Masculino , Pessoa de Meia-Idade
3.
Arch Facial Plast Surg ; 3(3): 165-9, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11497500

RESUMO

BACKGROUND: Facial laser resurfacing and chemodenervation with botulinum toxin type A are used independently as means of nonsurgical facial rejuvenation. Recent reports in the literature have described combining these 2 therapies, claiming improved and longer-lasting laser resurfacing results. To date, no scientific investigation has been undertaken to prove or disprove this theory. DESIGN: Institutional review board-approved, prospective, randomized, blinded study at university-affiliated outpatient cosmetic surgery offices. INTERVENTION: Patients had one side of their face injected, at specific anatomic subsites (crow's feet, horizontal forehead furrows, and glabellar frown lines), with botulinum toxin 1 week before laser resurfacing. After receiving an injection, patients underwent cutaneous laser exfoliation on both sides of the face with either a carbon dioxide or an erbium dual-mode laser. MAIN OUTCOME MEASURES: Patients' injected (experimental) and noninjected (control) sides were compared after laser resurfacing. Follow-up was documented at 6 weeks, 3 months, and 6 months after laser resurfacing. Subjective evaluation, based on a visual analog scale, was performed in person by a blinded observer. Furthermore, a blinded panel of 3 expert judges (1 facial plastic surgeon, 1 oculoplastic surgeon, and 1 cosmetic dermatologist) graded 35-mm photographs taken during postoperative follow-up visits. RESULTS: Ten female patients were enrolled in the study. A 2-tailed t test showed that all sites that were pretreated with botulinum toxin showed statistically significant improvement (P< or =.05) over the nontreated side, with the crow's feet region showing the greatest improvement. Comparing results between the carbon dioxide and erbium lasers did not result in any statistically significant differences. CONCLUSIONS: Hyperdynamic facial lines, pretreated with botulinum toxin before laser resurfacing, heal in a smoother rhytid-diminished fashion. These results were clinically most significant in the crow's feet region. We recommend pretreatment of movement-associated rhytides with botulinum toxin before laser resurfacing. For optimum results, we further recommend continued maintenance therapy with botulinum toxin postoperatively.


Assuntos
Toxinas Botulínicas Tipo A/administração & dosagem , Músculos Faciais/efeitos dos fármacos , Terapia a Laser , Ritidoplastia/métodos , Envelhecimento da Pele/efeitos dos fármacos , Adulto , Feminino , Humanos , Injeções , Pessoa de Meia-Idade , Fármacos Neuromusculares/administração & dosagem , Período Pós-Operatório , Estudos Prospectivos , Método Simples-Cego
5.
Otolaryngol Head Neck Surg ; 122(3): 352-7, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10699809

RESUMO

Twenty-four cases of the tall cell variant (TCV), a subset of papillary thyroid carcinoma, were identified in a group of 624 patients with thyroid cancer. All pathology specimens were reviewed, and each patient's carcinoma was categorized according to characteristics on presentation, local recurrence, distant metastases, follow-up, and tumor-related mortality. The TCV group was compared with a historical control group (Mazzaferri and Jhiang: 1355 patients). The TCV group had a statistically higher percentage of stage 3 and 4 carcinoma, extrathyroidal invasion, and tumor size less than 1.5 cm than the control group. There was no statistical relationship between age greater than 50 years and stage in the TCV group. No relationship could be found between TCV histology and recurrence or mortality. These findings, combined with those of studies that link stage on presentation to poor outcomes, have led to our conclusion that TCV is an aggressive malignancy warranting appropriate treatment and close follow-up.


Assuntos
Carcinoma Papilar/patologia , Neoplasias da Glândula Tireoide/patologia , Adulto , Idoso , Carcinoma Papilar/classificação , Carcinoma Papilar/mortalidade , Feminino , Seguimentos , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Invasividade Neoplásica , Recidiva Local de Neoplasia/patologia , Estadiamento de Neoplasias , Taxa de Sobrevida , Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/classificação , Neoplasias da Glândula Tireoide/mortalidade
6.
Epilepsia ; 34(2): 381-4, 1993.
Artigo em Inglês | MEDLINE | ID: mdl-8384110

RESUMO

Fluoxetine was evaluated for anticonvulsant effects in a rat model of focally evoked complex partial seizures (CPS) secondarily generalized. Fluoxetine was administered intraperitoneally (i.p.) 1 h before seizures were induced by focal intracerebral application of the GABAA receptor antagonist, bicuculline methiodide (118 pmol) unilaterally into a discrete epileptogenic site in the deep prepiriform cortex ("area tempestas," AT) of rats. Significant dose-dependent protection from clonic motor seizures was obtained after 5-, 10-, and 20-mg/kg doses of fluoxetine, with 50% protection occurring after the 5-mg/kg dose. Suppression of electrographic seizure activity was concomitant with suppression of motor seizures. These observations support and extend previous findings of other investigators who showed that fluoxetine exerts anticonvulsant actions against maximal electroshock (MES) convulsions and audiogenic convulsions in genetically seizure-prone rodents.


Assuntos
Anticonvulsivantes , Fluoxetina/farmacologia , Sistema Límbico/fisiopatologia , Convulsões/prevenção & controle , Estimulação Acústica , Animais , Anticonvulsivantes/farmacologia , Bicuculina/farmacologia , Modelos Animais de Doenças , Eletrochoque , Epilepsias Parciais/fisiopatologia , Epilepsia Parcial Complexa/prevenção & controle , Epilepsia Generalizada/prevenção & controle , Fluoxetina/administração & dosagem , Injeções Intraperitoneais , Ratos , Receptores de GABA-A/efeitos dos fármacos , Receptores de GABA-A/fisiologia , Convulsões/induzido quimicamente , Convulsões/fisiopatologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA